Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.

@article{Ghoti2011IncreasedSH,
  title={Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.},
  author={Hussam Ghoti and Eitan Fibach and Mark E. Westerman and Olbina Gordana and Tomas Ganz and Eliezer A. Rachmilewitz},
  journal={British journal of haematology},
  year={2011},
  volume={153 1},
  pages={
          118-20
        }
}
Hepcidin is a major regulator of iron metabolism. We evaluated changes in serum hepcidin during 3 months of therapy with the iron-chelator deferasirox in patients with low-risk myelodysplastic syndrome and iron overload. Serum hepcidin was found to be high in these patients, correlated with their iron and oxidative status, and further increased by treatment with deferasirox. These findings support the concept that the hepcidin level represents a balance between the stimulating effect of iron… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment

  • Journal of the advanced practitioner in oncology
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Effects of Pregnancy and Lactation on Iron Metabolism in Rats.

  • BioMed research international
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 17 REFERENCES

Hepatitis C virus - induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity

S. Mitra, M. Gleeson, R. Desmond
  • Hepatology
  • 2008

Similar Papers

Loading similar papers…